摘要
为了研究原发CD5+弥漫大B细胞淋巴瘤(de novo CD5+DLBCL)的临床特征、治疗及预后的关系,回顾性分析经病理证实的10例原发CD5+DLBCL患者的临床资料和治疗效果及预后。结果表明:9例患者发病年龄超过60岁,均为Ann-Arbor/cotsword分期Ⅲ-Ⅳ病例,发病初骨髓累及5例;除1例治疗中断外,其余均使用了含利妥昔单克隆抗体的化疗方案,治疗后评价为:完全缓解5例,部分缓解2例,稳定2例,进展1例。8例患者在2年内复发或疾病进展死亡,其中3例出现中枢神经系统累及并导致死亡。中位生存期16(1-23)个月,预计2年生存期为20.4%。结论:原发CD5+DLBCL淋巴瘤临床少见,但预后差,应提高对原发CD5+DLBCL疾病的认识,探寻R-CHOP以外的治疗方案并加强中枢神经系统的防治。
To explore the clinical characteristics, diagnosis, treatment outcome and prognosis of de novo CD5 positive diffuse large B cell lymphoma（ CD5 ＋ DLBCL）, clinical data of 10 patients with pathologically confirmed CD5＋ DLBCL were retrospectively analyzed. The results indicated that 9 out of 10 patients were older than 60 years. All cases were in Ⅲ-Ⅳ stages according to Ann-Arbor Stageing System. Bone marrow biopsy with immunohistochemistry showed lymphoma involvement in 5 cases. Nine patients received chemotherapy with anti-CD20 monoclonal antibody （Rituximab） except one. Five cases achieved CR, two cases achieved PR, two cases achieved SD, one case achieved PD. Eight cases died within 2 years because of relapse or disease progression, in which 3 cases developed central nervous system lymphoma. The median survival time was 16 （1 -23） months, 2-year survival rate was 20.40%. It is concluded that de novo CD5 ＋ DLBCL is rare in clinic, but it is a kind of highly aggressive lymphoma with poor prognosis. So, new treatment strategy should be explored.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2013年第2期399-402,共4页
Journal of Experimental Hematology
